27932-00-9 Usage
Uses
Used in Pharmaceutical Industry:
(2,3-dihydro-1H-inden-5-yl) hydrogen phenylmalonate is used as an intermediate in the synthesis of Indanylcarbinicillin (S635000), a compound with demonstrated hypotensive effects in mammals. It is also utilized as a β-lactam antibiotic, which is a class of antibiotics known for their effectiveness in treating a wide range of bacterial infections.
In the synthesis of Indanylcarbinicillin, (2,3-dihydro-1H-inden-5-yl) hydrogen phenylmalonate plays a crucial role in the development of a drug that can help regulate blood pressure and provide antibiotic treatment. Its unique chemical properties make it a valuable component in the creation of new and innovative pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 27932-00-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,7,9,3 and 2 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 27932-00:
(7*2)+(6*7)+(5*9)+(4*3)+(3*2)+(2*0)+(1*0)=119
119 % 10 = 9
So 27932-00-9 is a valid CAS Registry Number.
InChI:InChI=1/C18H16O4/c19-17(20)16(13-5-2-1-3-6-13)18(21)22-15-10-9-12-7-4-8-14(12)11-15/h1-3,5-6,9-11,16H,4,7-8H2,(H,19,20)
27932-00-9Relevant academic research and scientific papers
Preparation, hydrolysis, and oral absorption of alpha-carboxy esters of carbenicillin.
Clayton,Cole,Elson,Hardy,Mizen,Sutherland
, p. 172 - 177 (2007/10/06)
Twelve alpha-carboxy esters of carbenicillin, a parenteral broad spectrum semisynthetic penicillin, were synthesized and examined as potential oral carbenicillin derivatives. The rates at which the esters were hydrolyzed in vitro to carbenicillin by animal and human tissues were compared and the carbenicillin serum levels arising after oral administration of the esters were measured in squirrel monkeys and human volunteer subjects. The alpha-carboxyphenyl ester of carbenicillin [carfecillin (British Pharmacopoeia approved name), BRL 3475] WAS SELECTED FOR FURTHER STUDY AND IS PRESENTLY UNDERGOING CLInical trial.
